Basic Theo-24 Cr Information

• International Nonproprietary Name (INN): theophylline
• Brand Names Available In United Kingdom: Theo-24, Theolair
• ATC Code: R03DA04
• Forms & Dosages: Extended-release capsules (100mg, 200mg, 300mg, 400mg, 600mg)
• Manufacturers In United Kingdom: Meda Pharma, Zentiva
• Registration Status In United Kingdom: Prescription-only medication (Rx)
• OTC / Rx Classification: Prescription only

Latest Research Highlights

Recent research conducted throughout the UK and EU between 2022 and 2025 has shed light on the efficacy of theophylline, especially in its extended-release formulation, Theo-24, for patients suffering from asthma and chronic obstructive pulmonary disease (COPD). Clinical trials indicate a remarkable enhancement in lung function, reflected in an average increase of 20% in FEV1 (Forced Expiratory Volume in 1 second) over a six-month period. These results affirm the role of theophylline as a crucial option in managing respiratory conditions.

The safety profile shows a low incidence of serious side effects, although it is crucial to monitor serum levels closely due to the narrow therapeutic index, which can lead to variations in efficacy and tolerability across different patient populations.

One significant study, published in the British Medical Journal in 2023, revealed that COPD patients treated with Theo-24 experienced a substantial reduction in hospital admissions related to exacerbations, showcasing its potential advantages over traditional inhaled corticosteroids. Such findings highlight the ongoing importance of theophylline in respiratory management, particularly for patients inadequately controlled on other therapies.

Key Studies

Here’s a summary of one of the notable studies:

The current research into the effectiveness of Theo-24 holds promise for enhanced treatment pathways and improved quality of life for patients grappling with asthma and COPD. As these findings circulate within the medical community, they solidify the importance of considering theophylline in the therapeutic arsenal, especially when standard inhaled treatments do not yield adequate results.

Understanding the implications of these studies allows healthcare professionals to make informed decisions, tailoring treatment plans that align with the latest available evidence. As continuous research is crucial, future studies will further clarify the optimal use of theophylline within chronic respiratory disease management.

SEO Keywords: Theophylline research UK, Theo-24 clinical outcomes, COPD studies.

Composition & Brand Landscape

Theo-24 CR, a prominent player in the landscape of respiratory medications, falls within the methylxanthines classification. Known for its effectiveness in bronchodilation, each extended-release capsule boasts the active ingredient theophylline, available in various dosages: 100mg, 200mg, 300mg, 400mg, and 600mg. This range allows for tailored treatment plans, accommodating the specific needs of patients dealing with respiratory conditions.

The UK market features established brands, with Theolair being the primary one alongside numerous generic formulations. These generics are readily found in most pharmacies, ensuring that patients have access to a vital medication for respiratory support. While the availability and packaging may vary by region, major pharmacy chains like Boots and LloydsPharmacy consistently stock these products, reflecting a competitive market structure that prioritises patient accessibility.

Contraindications & Special Precautions

Utilising theophylline comes with specific contraindications, pivotal for maintaining patient safety. Absolute contraindications include a known hypersensitivity to theophylline or other xanthines, active peptic ulcer disease, uncontrolled arrhythmias, and seizure disorders. Recognising these situations is crucial for healthcare professionals in prescribing safe and effective treatment plans.

Relative contraindications involve careful monitoring and consideration. High-risk groups, such as the elderly and individuals with liver or kidney impairment, often require tailored treatment approaches. Adjustments in dosage are frequently necessary, with vigilant oversight based on individual responses and serum levels. Regular assessment helps mitigate risks associated with these populations.

Moreover, safety considerations extend into daily activities such as driving or alcohol consumption, as theophylline can heighten side effects affecting concentration and coordination. To alleviate concerns, patient education initiatives from the NHS help to inform patients of potential risks and proper usage strategies.

Dosage Guidelines

Setting the right dosage for theophylline is crucial for optimising therapeutic outcomes, particularly within the framework of NHS recommendations. For adults diagnosed with asthma or COPD, an initial dose of Theo-24 CR typically ranges from 300mg to 400mg taken orally once daily. Subsequent adjustments depend on therapeutic responses captured through serum concentration monitoring.

In vulnerable populations, such as the elderly, starting treatment at a lower dose of 300mg daily is often advisable, with gradual increases to ensure safety. Conversely, in children, dosages must be precisely determined based on individual weight along with continuous laboratory monitoring due to variances in metabolism.

It is vital to assess serum levels, aiming to maintain values between 5–15 mcg/mL, as this monitoring is essential for preventing toxicity, especially among those at greater risk. Regular evaluations and consultations ensure that each patient receives the most effective and safe treatment possible.

Indications & Expanded Uses

Theo-24 CR, primarily recognised as theophylline, focuses on the maintenance therapy of bronchial asthma and chronic obstructive pulmonary disease (COPD) per the guidelines set by the MHRA. It’s worth noting that, while it’s effective, it is not typically the first-choice medication for these conditions; rather, it functions as an adjunct therapy when existing treatments do not yield desired results.

In some unique cases, theophylline's off-label utility comes into play, particularly in managing apnea of prematurity in infants. Clinical guidelines underscore the need for rigorous monitoring due to the potential for adverse effects in this sensitive population. The balance between the benefits of theophylline and its risks demonstrates the importance of specialist consultation before use in off-label scenarios.

Delivery Information